RESUMO
El propranolol, un betabloqueante no selectivo, sigue siendo la primera línea de tratamiento para el hemangioma infantil problemático. Sin embargo, aunque poco frecuente, un subgrupo de pacientes experimenta efectos secundarios indeseables, lo que despierta el interés sobre otros betabloqueantes selectivos. Presentamos una amplia serie de casos de 46 lactantes tratados con éxito con atenolol, un bloqueante selectivo beta-1
Propranolol, a non-selective beta-blocker, remains the first line of treatment for problematic infantile hemangioma. However, although rarely, a subset of patients experience undesirable side effects, raising interest in other selective beta-blockers. We present a large case series of 46 infants treated successfully with oral atenolol, a selective beta-1 blocker
Assuntos
Humanos , Masculino , Feminino , Lactente , Pré-Escolar , Atenolol/administração & dosagem , Hemangioma/tratamento farmacológico , Atenolol/antagonistas & inibidores , Antagonistas de Receptores Adrenérgicos beta 1 , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/complicações , Diarreia/complicaçõesRESUMO
Propranolol, a non-selective beta-blocker, remains the first line of treatment for problematic infantile hemangioma. However, although rarely, a subset of patients experience undesirable side effects, raising interest in other selective beta-blockers. We present a large case series of 46 infants treated successfully with oral atenolol, a selective beta-1 blocker.
Assuntos
Antagonistas de Receptores Adrenérgicos beta 1/administração & dosagem , Atenolol/administração & dosagem , Hemangioma Capilar/tratamento farmacológico , Neoplasias Cutâneas/tratamento farmacológico , Administração Oral , Feminino , Humanos , Lactente , MasculinoRESUMO
No disponible
Assuntos
Humanos , Masculino , Criança , Dermatopatias Virais/diagnóstico , Xantogranuloma Juvenil/diagnóstico , Mãos/patologia , Xantogranuloma Juvenil/patologia , Biópsia , Dermoscopia , Diagnóstico DiferencialRESUMO
No disponible
Assuntos
Humanos , Masculino , Feminino , Lactente , Pré-Escolar , Criança , Dermatopatias Papuloescamosas/patologia , Dermatopatias Papuloescamosas/diagnóstico , Dermatopatias Papuloescamosas/epidemiologia , Diagnóstico Diferencial , Peru/epidemiologia , Argentina/epidemiologiaAssuntos
Dermatopatias Vesiculobolhosas/patologia , Criança , Pré-Escolar , Feminino , Humanos , Lactente , MasculinoRESUMO
No disponible
Assuntos
Humanos , Feminino , Recém-Nascido , Hemangioma/patologia , Neoplasias Cutâneas/patologia , Meningomielocele/complicações , Comorbidade , Dermatite das Fraldas/diagnóstico , Fissura Anal/diagnósticoAssuntos
Hemangioma Capilar/etiologia , Síndromes Neoplásicas Hereditárias/etiologia , Neoplasias Cutâneas/etiologia , Feminino , Hemangioma Capilar/patologia , Humanos , Recém-Nascido , Meningomielocele/etiologia , Síndromes Neoplásicas Hereditárias/patologia , Neoplasias Cutâneas/patologia , Úlcera Cutânea/etiologiaRESUMO
BACKGROUND: Griseofulvin has been used for many years in the treatment of tinea capitis. Increase in resistance to this medication has led to a search for new therapeutic alternatives. OBJECTIVE: Our purpose was to evaluate the therapeutic efficacy of terbinafine in comparison with griseofulvin in the treatment of tinea capitis. METHODS: We performed a double-blind, randomized, prospective evaluation of 50 patients with a clinical and mycologic diagnosis of tinea capitis. One group received 4 weeks of terbinafine followed by 4 weeks of placebo. The other group received 8 weeks of griseofulvin. We evaluated 5 clinical parameters. Mycologic examinations were performed at baseline and at the end of weeks 8 and 12. RESULTS: Patients' ages ranged from 1 to 14 years. Fifty-four percent were girls and 46% were boys. Mycologic examinations disclosed Trichophyton tonsurans in 74% of patients and Microsporum canis in 26%. At week 8, the griseofulvin-treated group showed a cure rate of 76%, and the terbinafine-treated group 72%. At week 12, the efficacy of griseofulvin decreased to 44%, whereas the efficacy of terbinafine was 76%. CONCLUSION: Terbinafine constitutes an alternative for the treatment of tinea capitis. Recurrences were less frequent. No significant side effects were reported.
